Jaiswal Vikash, Almas Talal, Peng Ang Song, Shama Nishat, Storozhenko Tatyana, Lnu Kriti, Parmar Garima, Qaiser Saria, Naz Sidra, Jaiswal Akash, Malik Jahanzeb
AMA School of Medicine, Makati, Philippines.
Royal College of Surgeons in Ireland, Dublin, Ireland.
Ann Med Surg (Lond). 2022 Apr;76:103429. doi: 10.1016/j.amsu.2022.103429. Epub 2022 Mar 8.
There is an increasing COVID-19 population with concurrent STEMI. SARS-CoV-2 poses a significant risk of hypercoagulable and/or prothrombotic events due to the disturbance in hemostasis by affecting all three components of the Virchow's triad. These abnormalities in hemostasis are an increased risk factor for cardiovascular events, including acute thrombotic occlusion of coronary arteries leading to myocardial infarction.
The objective of this study is to collate the prognosis, symptomatology and clinical findings of COVID-19 adverse events causing STEMI.
Databases were queried with various keyword combinations to find applicable articles. Cardiovascular risk factors, symptomatology, mortality and rates of PCI were analyzed using random-effect model.
15 studies with a total of 379 patients were included in the final analysis. Mean age of patients was 62.82 ± 36.01, with a male predominance (72%, n = 274). Hypertension, dyslipidemia and diabetes mellitus were the most common cardiovascular risk factors among these patients, with a pooled proportion of 72%, 59% and 40% respectively. Dyspnea (61%, n = 131) was the most frequent presenting symptom, followed by chest pain (60%, n = 101) and fever (56%, n = 104). 62% of the patients had obstructive CAD during coronary angiography. The primary reperfusion method used in the majority of cases was percutaneous coronary intervention (64%, n = 124). Mortality, which is the primary outcome in our study, was relatively high, with a rate of 34% across studies.
Our findings show that most cases have been found in males, while the most common risk factors were Hypertension and Diabetes Mellitus. In most COVID-19 cases with ST-segment myocardial infarction, most hospitalized patients underwent primary percutaneous coronary intervention instead of fibrinolysis. The in-hospital mortality was significantly higher, making this report significant. As the sample size and reported study are considerably less, it warrants a further large-scale investigation to generalize it.
新型冠状病毒肺炎(COVID-19)合并ST段抬高型心肌梗死(STEMI)的患者日益增多。严重急性呼吸综合征冠状病毒2(SARS-CoV-2)通过影响维勒氏三联征的所有三个组成部分干扰止血,从而带来显著的高凝和/或血栓形成风险。这些止血异常是心血管事件的一个增加的风险因素,包括导致心肌梗死的冠状动脉急性血栓闭塞。
本研究的目的是整理导致STEMI的COVID-19不良事件的预后、症状学和临床发现。
用各种关键词组合查询数据库以查找适用的文章。使用随机效应模型分析心血管危险因素、症状学、死亡率和经皮冠状动脉介入治疗(PCI)率。
最终分析纳入了15项研究,共379例患者。患者的平均年龄为62.82±36.01岁,男性占多数(72%,n = 274)。高血压、血脂异常和糖尿病是这些患者中最常见的心血管危险因素,合并比例分别为72%、59%和40%。呼吸困难(61%,n = 131)是最常见的首发症状,其次是胸痛(60%,n = 101)和发热(56%,n = 104)。62%的患者在冠状动脉造影时患有阻塞性冠状动脉疾病。大多数病例使用的主要再灌注方法是经皮冠状动脉介入治疗(64%,n = 124)。死亡率是我们研究的主要结局,相对较高,各研究的死亡率为34%。
我们的研究结果表明,大多数病例为男性,最常见的危险因素是高血压和糖尿病。在大多数COVID-19合并ST段心肌梗死的病例中,大多数住院患者接受了直接经皮冠状动脉介入治疗而非溶栓治疗。住院死亡率显著更高,使得本报告具有重要意义。由于样本量和报道的研究相当少,有必要进行进一步的大规模调查以推广本研究结果。